Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2017

Open Access 01-12-2017 | Research

The waist circumference-adjusted associations between hyperuricemia and other lifestyle-related diseases

Authors: Taiju Miyagami, Hirohide Yokokawa, Kazutoshi Fujibayashi, Toshiaki Gunji, Noriko Sasabe, Mitsue Okumura, Kimiko Iijima, Toshio Naito

Published in: Diabetology & Metabolic Syndrome | Issue 1/2017

Login to get access

Abstract

Background

Few studies have assessed the associations between hyperuricemia and lifestyle-related diseases after adjusting for waist circumference (WC) and sex.

Methods

This cross-sectional study included 33,498 Japanese individuals, and was conducted at the Center for Preventive Medicine, NTT Kanto Medical Center, Tokyo, from May 2006 to March 2015. Hyperuricemia was defined as a uric acid level of >7 mg/dl in men; >6 mg/dl in women. Metabolic syndrome (Mets) components were defined using the Japanese criteria for Mets. The subjects were stratified into quartiles according to their WC as follows: males: <78.4, 78.4 to <83.5, 83.5 to <89, and ≥89 cm; females: <71.6, 71.6 to <77, 77 to <83.2, and ≥83.2 cm. The relationships between these quartiles and the presence of ≥2 components of Mets or hyperuricemia were then evaluated using Chi square analysis. The presence of ≥2 components of Mets were then determined using multivariate logistic regression analysis adjusting for age, the presence of hyperuricemia, WC, and lifestyle habits.

Results

Hyperuricemia was found to be an independent predictor of lifestyle-related diseases after adjusting for age, WC, and lifestyle in both sexes. Males: a uric acid level of >7 mg/dl (odds ratio [OR]: 1.70, 95% confidence interval [CI]: 1.57–1.83), Females: a uric acid level of >6 mg/dl (OR: 2.35, 95% CI 1.83–2.99).

Conclusion

Hyperuricemia was found to be an independent predictor of several lifestyle-related diseases, even after adjusting for WC which is closely related with insulin resistance. Hyperuricemia might require greater attention during the prevention of lifestyle-related diseases and future cardiovascular disease.
Literature
1.
go back to reference Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403–6.PubMed Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403–6.PubMed
3.
go back to reference Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.CrossRefPubMed Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.CrossRefPubMed
4.
go back to reference Lim SY, Lu N, Oza A, Fisher M, Rai SK, Menendez ME, et al. Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993–2011. JAMA. 2016;315:2345–7.CrossRefPubMedPubMedCentral Lim SY, Lu N, Oza A, Fisher M, Rai SK, Menendez ME, et al. Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993–2011. JAMA. 2016;315:2345–7.CrossRefPubMedPubMedCentral
5.
go back to reference The guideline revision committee. Japanese Society of Gout and Nucleic Acid Metabolism. Recent trend and risk of hyperuricemia and/or gout. 2nd ed. Tokyo: Guideline for the management of hyperuricemia and gout; 2010. p. 30–6. The guideline revision committee. Japanese Society of Gout and Nucleic Acid Metabolism. Recent trend and risk of hyperuricemia and/or gout. 2nd ed. Tokyo: Guideline for the management of hyperuricemia and gout; 2010. p. 30–6.
6.
go back to reference Hikita M, Ohno I, Mori Y, Ichida K, Yokose T, Hosoya T. Relationship between hyperuricemia and body fat distribution. Intern Med. 2007;46:1353–8.CrossRefPubMed Hikita M, Ohno I, Mori Y, Ichida K, Yokose T, Hosoya T. Relationship between hyperuricemia and body fat distribution. Intern Med. 2007;46:1353–8.CrossRefPubMed
7.
go back to reference Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27:835–41.CrossRefPubMed Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27:835–41.CrossRefPubMed
8.
go back to reference Acevedo A, Benavides J, Chowdhury M, Lopez M, Pena L, Montenegro A, et al. Hyperuricemia and cardiovascular disease in patients with hypertension. Conn Med. 2016;80:85–90.PubMed Acevedo A, Benavides J, Chowdhury M, Lopez M, Pena L, Montenegro A, et al. Hyperuricemia and cardiovascular disease in patients with hypertension. Conn Med. 2016;80:85–90.PubMed
9.
go back to reference Yokokawa H, Fukuda H, Suzuki A, Fujibayashi K, Naito T, Uehara Y, et al. Association between serum uric acid levels/hyperuricemia and hypertension among 85,286 Japanese workers. J Clin Hypertens (Greenwich). 2016;18:53–9.CrossRef Yokokawa H, Fukuda H, Suzuki A, Fujibayashi K, Naito T, Uehara Y, et al. Association between serum uric acid levels/hyperuricemia and hypertension among 85,286 Japanese workers. J Clin Hypertens (Greenwich). 2016;18:53–9.CrossRef
10.
go back to reference Zhi L, Yuzhang Z, Tianliang H, Hisatome I, Yamamoto T, Jidong C. High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo. PLoS ONE. 2016;11:e0147737.CrossRefPubMedPubMedCentral Zhi L, Yuzhang Z, Tianliang H, Hisatome I, Yamamoto T, Jidong C. High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo. PLoS ONE. 2016;11:e0147737.CrossRefPubMedPubMedCentral
11.
go back to reference Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69:928–33.CrossRefPubMed Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69:928–33.CrossRefPubMed
12.
go back to reference Zoccali C, Mallamaci F. Uric acid, hypertension, and cardiovascular and renal complications. Curr Hypertens Rep. 2013;15:531–7.CrossRefPubMed Zoccali C, Mallamaci F. Uric acid, hypertension, and cardiovascular and renal complications. Curr Hypertens Rep. 2013;15:531–7.CrossRefPubMed
13.
go back to reference Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11–7.CrossRefPubMed Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11–7.CrossRefPubMed
14.
go back to reference Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Relation between serum uric acid and carotid intimamedia thickness in healthy postmenopausal women. Intern Emerg Med. 2007;2:19–23.CrossRefPubMedPubMedCentral Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Relation between serum uric acid and carotid intimamedia thickness in healthy postmenopausal women. Intern Emerg Med. 2007;2:19–23.CrossRefPubMedPubMedCentral
15.
16.
go back to reference Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. 2008;29:777–822.CrossRefPubMed Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. 2008;29:777–822.CrossRefPubMed
17.
go back to reference Matsuzawa Y. Metabolic syndrome—definition and diagnostic criteria in Japan. J Atheroscler Thromb. 2005;12:301.CrossRefPubMed Matsuzawa Y. Metabolic syndrome—definition and diagnostic criteria in Japan. J Atheroscler Thromb. 2005;12:301.CrossRefPubMed
18.
go back to reference Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and Metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33.CrossRefPubMed Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and Metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33.CrossRefPubMed
19.
go back to reference You L, Liu A, Wuyun G, Wu H, Wang P. Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area. J Atheroscler Thromb. 2014;21:355–65.CrossRefPubMed You L, Liu A, Wuyun G, Wu H, Wang P. Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area. J Atheroscler Thromb. 2014;21:355–65.CrossRefPubMed
20.
go back to reference Gonçalves JP, Oliveira A, Severo M, Santos AC, Lopes C. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine. 2012;41:450–7.CrossRefPubMed Gonçalves JP, Oliveira A, Severo M, Santos AC, Lopes C. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine. 2012;41:450–7.CrossRefPubMed
21.
go back to reference Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737–42.CrossRefPubMedPubMedCentral Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737–42.CrossRefPubMedPubMedCentral
22.
go back to reference Yadav D, Lee ES, Kim HM, Choi E, Lee EY, Lim JS, et al. Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. Atherosclerosis. 2015;241:271–7.CrossRefPubMed Yadav D, Lee ES, Kim HM, Choi E, Lee EY, Lim JS, et al. Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. Atherosclerosis. 2015;241:271–7.CrossRefPubMed
23.
go back to reference Yu TY, Jee JH, Bae JC, Jin SM, Baek JH, Lee MK, et al. Serum uric acid: a strong and independent predictor of metabolic syndrome after adjusting for body composition. Metabolism. 2016;65:432–40.CrossRefPubMed Yu TY, Jee JH, Bae JC, Jin SM, Baek JH, Lee MK, et al. Serum uric acid: a strong and independent predictor of metabolic syndrome after adjusting for body composition. Metabolism. 2016;65:432–40.CrossRefPubMed
24.
go back to reference Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290:F625–31.CrossRefPubMed Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290:F625–31.CrossRefPubMed
25.
go back to reference Definition and the diagnostic standard for metabolic syndrome–Committee to Evaluate Diagnostic Standards for Metabolic Syndrome]. Nihon Naika Gakkai Zasshi. 2005;94: 794–809. (In Japanese). Definition and the diagnostic standard for metabolic syndrome–Committee to Evaluate Diagnostic Standards for Metabolic Syndrome]. Nihon Naika Gakkai Zasshi. 2005;94: 794–809. (In Japanese).
26.
go back to reference Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26:186–91.CrossRefPubMed Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26:186–91.CrossRefPubMed
28.
go back to reference Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, et al. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab. 2015;100:4198–207.CrossRefPubMed Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, et al. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab. 2015;100:4198–207.CrossRefPubMed
29.
go back to reference Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS ONE. 2014;9:e114259.CrossRefPubMedPubMedCentral Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS ONE. 2014;9:e114259.CrossRefPubMedPubMedCentral
30.
go back to reference Antón FM, García Puig J, Ramos T, González P, Ordás J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986;35:343–8.CrossRefPubMed Antón FM, García Puig J, Ramos T, González P, Ordás J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986;35:343–8.CrossRefPubMed
31.
go back to reference Yadav D, Lee ES, Kim HM, Choi E, Lee EY, Lim JS, Chung CH, et al. Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. Atherosclerosis. 2015;241:271–7.CrossRefPubMed Yadav D, Lee ES, Kim HM, Choi E, Lee EY, Lim JS, Chung CH, et al. Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. Atherosclerosis. 2015;241:271–7.CrossRefPubMed
Metadata
Title
The waist circumference-adjusted associations between hyperuricemia and other lifestyle-related diseases
Authors
Taiju Miyagami
Hirohide Yokokawa
Kazutoshi Fujibayashi
Toshiaki Gunji
Noriko Sasabe
Mitsue Okumura
Kimiko Iijima
Toshio Naito
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2017
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-017-0212-6

Other articles of this Issue 1/2017

Diabetology & Metabolic Syndrome 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.